Cell and Gene Therapy Chain of Identity Needs a Verifiable Handoff
Cell and gene therapy programmes need a chain of identity that stays visible from collection through release, treatment, and follow-up.
56 results matched the archive and page content.
Cell and gene therapy programmes need a chain of identity that stays visible from collection through release, treatment, and follow-up.
Biomanufacturing single-use systems are useful only when material choice, process fit, supplier change, and quality review remain connected.
Clinical biomarker validation becomes decision-ready when the intended use, specimen, threshold, population, and action are defined together.
Biosimilar interchangeability is not only a product question. It also depends on prescribing, dispensing, records, communication, and follow-up.
Biorepository sample governance works when consent, identity, storage, access, use, and disposition can be traced without ambiguity.
Synthetic biology containment needs a practical operating boundary that connects design, facility controls, training, incident response, and review.
Companion diagnostics evidence matters when the test result changes a defined treatment decision for the population being served.
Genomic data consent needs a clear reuse boundary so participants, researchers, custodians, and downstream users understand what may happen next.
Therapeutic protein immunogenicity assessment is strongest when sampling, interpretation, clinical context, and follow-up are designed as one pathway.
Cell processing facilities need a release-readiness record that joins identity, quality, environmental control, deviations, and the treatment decision.
Explore insights on the global healthcare contract manufacturing market, focusing on trends, growth drivers, and key industry players.
Explore the global AI in healthcare market trends by offerings, algorithms, end-use industries, and regions in our comprehensive forecast report.